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ABSTRACT 
Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is 
considered a major limitation for virotherapy of disseminated cancers. The benefit of using 
mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only 
in preclinical models but also in clinical trials. In this context, we have previously demonstrated 
the enhanced antitumor efficacy of OAdv-loaded menstrual blood-derived mesenchymal stem 
cells (MenSCs). However, although significant, the antitumor efficacy obtained was modest, and 
we hypothesized that a greater antitumor efficacy could be obtained arming the OAdv with a 
therapeutic transgene. Here we show that combining MenSCs with ICOVIR15-cBiTE, an OAdv 
expressing an epidermal growth factor receptor (EGFR)-targeting bispecific T-cell engager 
(cBiTE), enhances the antitumor efficacy compared to MenSCs loaded with the unarmed virus 
ICOVIR15. We found that MenSCs properly produce cBiTE after viral infection leading to a 
greater antitumor potency both in vitro and in vivo. These findings indicate the mutual benefit of 
combining MenSCs and armed OAdv and support the combination of ICOVIR15-cBiTE and 
MenSCs as a cancer treatment.  
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INTRODUCTION 
Oncolytic adenoviruses (OAdv) have been extensively studied in clinical trials for the treatment 
of different cancer types, revealing good toxicological and safety profiles, but modest efficacy.1 
A key limitation upon OAdv systemic administration is virus biodistribution. Poor tumor 
targeting and limited tumor penetration contribute to such inefficacy.2 The antiviral immune 
response also represents an important barrier for OAdv. Thus, the immune system can recognize 
the adenovirus in the bloodstream leading to its elimination. In particular, neutralizing antibodies 
raised after the first administration prevent the efficacy of subsequent doses. Moreover, virus 
replication within the tumor also triggers a potent antiviral response that limits ongoing infection 
of tumor cells, becoming dominant over tumor-specific immunity.3  
The use of cell carriers to deliver oncolytic viruses to primary tumors and metastasis has been 
evaluated in order to overcome these obstacles. In this regard, mesenchymal stem cells (MSCs) 
have garnered interest as OAdv cell carriers given their natural tumor tropism and immunogenic 
properties.4 We have recently reported the advantages of using menstrual blood-derived 
mesenchymal stem cells (MenSCs) as cell carriers for ICOVIR15, an OAdv developed in our 
laboratory.5 We demonstrated not only an efficient OAdv tumor delivery, but also a significant, 
although modest, antitumor efficacy of OAdv-loaded MenSCs in combination with human 
peripheral blood mononuclear cells (hPBMCs). This increased antitumor effect was mainly 
mediated by monocyte activation leading to both T cell and natural killer cell activation.5   
In a different line of research aimed at redirecting T cells towards tumor cells, we have recently 
engineered an armed OAdv (ICOVIR15K-cBiTE) expressing an epidermal growth factor 
receptor (EGFR)-targeting bispecific T-cell engager (cBiTE).6 BiTEs are well-established 
immunotherapeutic molecules that combine the minimal binding domains (scFv) of two different 
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monoclonal antibodies fused by a short flexible linker.7 One of the scFv recognizes the TCR 
CD3ε subunit whereas the second scFv targets tumor-associated antigens on cancer cells, leading 
to T-cell activation and target cell lysis. The major histocompatibility complex class I-
independent and polyclonal mode of action of BiTEs,8 offers the opportunity to redirect 
adenovirus-specific cytotoxic T lymphocytes to cancer cells. Our work revealed that 
ICOVIR15K-cBITE induces robust and specific-T cell activation and proliferation upon cancer 
cell infection, increasing the antitumor efficacy of the virus, both in vitro and in vivo.6   
Combining these strategies, this study compares the antitumor efficacy of a cBiTE-armed 
(ICOVIR15-cBiTE) versus the unarmed (ICOVIR15) OAdvs in combination with MenSCs as 
cells carriers in the presence of hPBMCs. We show that MenSCs properly deliver both OAdvs to 
the tumor, allowing tumor viral replication and cBiTE production from the armed virus-infected 
cells. Enhanced antitumor efficacy is observed when the cBiTE-expressing OAdv is combined 
with MenSCs, demonstrating the potential benefit of using ICOVIR15-cBiTE-loaded MenSCs to 
improve the treatment outcome.   
 
MATERIALS AND METHODS 
Cell lines and viruses 
The cancer cell lines A549 (human lung adenocarcinoma) and A431 (epidermoid carcinoma) 
were obtained from the American Type Culture Collection (ATCC, Manassas, VA). A431-GL 
was generated by sorting A431 cells previously transduced with a lentiviral vector encoding GFP 
and luciferase. All tumor cell lines were maintained with Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Thermo Fisher 
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Scientific, Waltham, MA, USA) at 37ºC, 5% CO2. Cell lines were routinely tested for 
mycoplasma presence. Isolation and characterization of MenSCs has been previously described.5  
Experiments employing human PBMCs were approved by the ethics committees of the 
University Hospital of Bellvitge and the Blood and Tissue Bank (BST) from Catalonia. PBMCs 
of healthy donors were isolated from blood by ficoll (Rafer, Spain) density gradient 
centrifugation in Leucosep tubes (Greiner Bio-one, Kremsmünster, Austria) following the 
manufacturer’s recommendations. T cells were isolated using the Rosette-Set Human T Cell 
Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada). For stimulation, T cells 
were cultured with CD3/CD28-activating Dynabeads (Thermo Fisher Scientific) at 1:3 bead-to 
cell ratio. 
The oncolytic adenovirus ICOVIR15 have been previously described. 5  ICOVIR15-cBiTE was 
engineered to express cBiTE gene under the control of the viral major late promoter by 
homologous recombination in bacteria, similarly to previous described for ICOVIR15K-BiTE. 6 
Production of supernatants 
A549 or MenSCs (2.5x106) were infected with ICOVIR15 or ICOVIR15-cBiTE (MOI=5 or 50 
respectively) and supernatants were harvested 72 hours after infection. For binding assays, 
supernatants were concentrated 20x with Amicon Ultra-15 filter units with a molecular weight 
cut-off of 30 kDa (Merck Millipore, Darmstadt, Germany). Supernatants from uninfected cells 
were used as a negative mock control. 
Binding assay 
Target cells (A549 cells, 2x105) were incubated with supernatants (generated from infected A549 
cells) for 1 hour on ice. Cells were stained with the monoclonal M2 anti-FLAG antibody (Sigma 
Aldrich, St.Louis, MO, USA) as primary antibody and a goat anti-mouse IgG as secondary 
antibody (Thermo Fisher Scientific). Cells were analysed with a Gallios cytometer (Beckman 
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Coulter, Brea, Ca, USA). The FlowJo software (Tree Star, Ashland, OR, USA) was used for data 
analysis.  
Virus cytotoxicity assays 
Virus cytotoxicity assay were performed as previously described. 6 The inhibitory concentration 
50 (IC50) was calculated with GraphPad Prism v6.02 (GraphPad Software Inc.) by a dose-
response nonlinear regression with a variable slope. 
To assess the cBiTE-mediated cytotoxicity, A431-GL target cells (3x104) were co-cultured with 
1.5x105 T-cells (E:T=5) in 96-well plates. Co-cultures were mixed with 100μl of mock, 
ICOVIR15, or ICOVIR15-cBiTE supernatants (generated from MenSCs infected with the 
corresponding viruses). After 24h of incubation, cocultures were trypsinized and stained with 
LIVE/DEAD (Thermo Fisher Scientific). Viable GFP-expressing tumor cells were determined 
by flow cytometry (negative for LIVE/DEAD and positive for GFP). CountBright Absolute 
Counting Beads (Thermo Fisher Scientific) were used for absolute cell number determination. 
Cytotoxicity was expressed as the percentage of live cancer cells in co-cultures normalized to 
cancer cells cultured alone.  
In vivo studies 
In vivo studies were performed at the ICO-IDIBELL animal facility (Barcelona, Spain) 
AAALAC unit 1155 and approved by IDIBELL’s Ethical Committee for Animal 
Experimentation.  
Lung adenocarcinoma xenograft tumors were established by implanting 5×106 A549 cells 
subcutaneously into both flanks of 8-week-old NOD scid gamma (NSG) mice. When tumors 
reached 100-120 mm3, mice were randomized and distributed into groups. To evaluate systemic 
antitumor efficacy, 1x107 human allogeneic PBMCs were administered to the mice by 
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intravenous injection. The next day, animals were treated with a single intraperitoneal dose of 
PBS, 1×1010 vp/mice of OAdv (ICOVIR15 or ICOVIR15-cBiTE) or MenSC/OAdv (5x106 cells 
previously infected with ICOVIR15 or ICOVIR15-cBiTE at MOI 50 for 24h).  
Tumor volume was calculated according to the equation V(mm3) =π/6×W2×L, where W and L 
are the width and the length of the tumor, respectively. Data are expressed as the tumor size 
relative to the size at the beginning of the therapy (tumor growth). At the end of the study, 
animals were euthanized and tumors were collected. One half was frozen for DNA/RNA 
extraction, and the other half was fixed in 4% formaldehyde for 24h and embedded in paraffin. 
DNA/RNA quantification by qPCR 
Frozen tumor samples were disrupted using a mortar and pestle under liquid nitrogen. RNA and 
DNA were isolated with the DNA/RNA/protein kit (IBI Scientific, Dubuque, IA, USA) from 
approximately 25mg of homogenized tissue. RNA samples were treated with the TURBO DNA-
free kit (Thermo Fisher Scientific) to remove traces of genomic DNA. RNA (1µg) was 
retrotranscribed with the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher 
Scientific). Real-time analysis was performed in a LightCycler 480 Instrument II (Roche, Basel, 
Switzerland) in the presence of SYBR Green I Master (Roche). To quantify viral genomes and 
E1A/cBiTE transcripts in the tumor, 100ng of DNA and 40ng of cDNA were used, respectively. 
PCR conditions were: 95ºC 10 minutes, 40x cycles of 95ºC 15 seconds, 60ºC 1 minute and 72ºC 
7 minutes. Viral genome primers were Ad18852: 5’-CTTCGATGATGCCGCAGTG-3’ and 
Ad19047R: 5’-ATGAACCGCAGCGTCAAACG-3’. E1A primers were qE1AF: 5’-
ATCGAAGAGGTACTGGCTGA-3’ and qE1AR: 5’-CCTCCGGTGATAATGACAAG-3’; 
cBiTE primers were qBiTEF: 5’-CGGCGAGAAAGTGACAATGAC-3’ and qBiTER: 5’-
TTGGTGAGGTGCCACTTTTC-3’ and b-actin primers were ACBTF: 5´- 
CTGGAACGGTGAAGGTGACA-3`and ACTBR 5´-GGGAGAGGACTGGGCCATT-3`. 
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Standard curves for viral genomes were prepared by serial dilutions of known copy numbers of a 
plasmid containing the adenovirus genome. β-actin expression was used to normalize E1a and 
cBiTE gene expression. In all cases, non-retrotranscribed RNA samples, equivalent to the 
amount cDNA loaded in the PCR, were run to discard genomic DNA contamination. 
Histology and immunohistochemistry  
A549 paraffin-embedded sections (5-μm thickness) of tumors sample were treated with an anti-
Ad2/5E1A (SC-430, Santa Cruz Biotechnology) as primary antibody. Immunohistochemical 
staining was performed with EnVision (DAKO, Hamburg, Germany), according to 
manufacturers’ instructions, and with hematoxylin. Images were acquired using the Nikon 
Eclipse 80i microscope running NIS elements BR software (Nikon Instruments Europe BV, 
Amsterdam, Netherlands). 
Statistical analysis 
Statistical comparisons between two groups were performed using the Mann-Whitney U test. For 
comparison of more than two groups, Kruskal-Wallis with Dunn post-hoc test was used. 
Statistical significance was established as p<0.05. Data are presented as the mean ±SD or SEM. 
All statistical analysis were calculated with GraphPad Prism software. 
 
RESULTS  
Generation and characterization of ICOVIR15-cBiTE generated from infected MenSCs. 
The parental oncolytic adenovirus, ICOVIR15, has been previously described.5 This virus is an 
E1a-Δ24-based oncolytic adenovirus with palindromic E2F binding sites in the E1a promoter 
and an insertion of Arg-Gly-Asp (RGD) in the HI-loop of the fiber knob that has shown a higher 
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MenSCs infection capability.9 We engineered this virus to express an EGFR-targeting bispecific 
T-cell engager (cBiTE) under the control of the adenovirus major late promoter (Figure 1a).  
To evaluate whether cBiTE insertion affected viral oncolytic properties, a dose-dependent 
cytotoxicity assay was performed. As shown in figure 1b, ICOVIR15-cBiTE retained oncolytic 
properties in vitro compared with its parental counterpart. We also compared virus production 
(both armed and parental virus) in MenSCs and A549 cell line (a highly permissive cell line 
commonly used for OAdv production). The total production of ICOVIR15 compared to 
ICOVIR15-cBiTE was similar for each cell line (mean of 4475 TU/cell vs 4185 TU/cell for 
ICOVIR15 and ICOVIR15-cBiTE on A549, and 2910 TU/cell vs 2475 TU/cell on MenSCs) 
indicating that cBiTE transgen insertion into ICOVIR15 genome does not affect total virus 
production (supplementary figure 1). Moreover, similar lower viral production was determined 
for both virus in MenSCs compared to A549 (1.5 and 1.6-fold decrease in production for 
ICOVIR15 and ICOVIR15-cBiTE, respectively, in MenSCs compared to A549), as previously 
described.9   
We next determined whether the cBiTE encoded by ICOVIR15-cBiTE was properly secreted by 
MenSCs infected cells while retaining its EGFR-antigen binding property. For this purpose, flow 
cytometry–based binding assays were performed by using the FLAG tag fused to the cBiTE. 
Correct cBiTE binding to A549-EGFR+ was detected only in the supernatants of ICOVIR15-
cBiTE-infected MenSCs (figure 1c).  
We next investigated the cBiTE-mediated cytotoxicity in vitro. To avoid the interference of 
virus-mediated cytotoxicity, we chose as a target the A431-GL EGFR+ cell line, which is partly 
resistant to adenovirus infection because of its low coxsackievirus-adenovirus receptor 
expression. A431-GL cells were co-cultured with T-cells in the presence of supernatants 
obtained from non-infected (mock) or ICOVIR15/ICOVIR15-cBiTE-infected MenSCs. A 
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significant cytotoxicity was observed after 24h of incubation only in the presence of ICOVIR15-
cBiTE supernatant (figure 1d). This result indicates that once cBiTE is expressed and secreted 
from infected cells, it can successfully lead to T-cell-mediated cytotoxicity of EGFR-expressing 
cells. 
ICOVIR15-cBITE-loaded MenSCs enhances in vivo antitumor efficacy 
We have recently reported the tumor homing properties and antitumor efficacy of ICOVIR15-
loaded MenSCs after systemic administration in human tumor-bearing NSG mice in the presence 
of human PBMCs.9  To determine whether cBiTE production from ICOVIR15-cBiTE infected 
MenSCs improved the previously described antitumor efficacy, NSG mice bearing subcutaneous 
A549 tumors were intravenously injected with human PBMCs and 24h later intraperitoneally 
treated with PBS (control group), ICOVIR15, ICOVIR15-cBiTE, MenSCs/ICOVIR15 (MenSCs 
previously infected with ICOVIR15 at MOI 50 for 24h), or MenSCs/ICOVIR15-cBiTE 
(MenSCs previously infected with ICOVIR15-cBiTE at MOI 50 for 24h). During the first week 
after treatment, all groups showed a tendency to control tumor growth compared to the control 
group, but differences were only statistically significant for the MenSCs/ICOVIR15-cBiTE 
group. Notably, from day 7 until the end of the experiment, although MenSCs/ICOVIR15 
demonstrated improved tumor growth control compared to PBS and ICOVIR15 groups (1.2-fold 
decrease versus both groups), only the group treated with MenSCs/ICOVIR15-cBiTE showed a 
significant reduction in tumor growth compared to PBS (1.9-fold decrease) and to other 
treatment groups (1.9, 1.7, and 1.6-fold decrease versus ICOVIR15, ICOVIR15-cBiTE, and 
MenSCs/ICOVIR15, respectively) (figure 1e). Histology analysis of the tumors at the end of the 
experiment revealed the expression of the E1a protein in tumors of animals treated with the 
oncolytic adenovirus ICOVIR15 and ICOVIR15-cBiTE alone or in combination with MenSCs, 
confirming the correct delivery and amplification of both viruses in tumors (figure 1f). 
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Moreover, transcript analysis of collected tumors indicated correct viral transcripts (E1a) 
production in OAdv treated animals and, as expected, transgene transcript (cBiTE) generation 
only in ICOVIR15-cBiTE treated animals (figure 1g). However, when ICOVIR15-cBiTE was 
used, the amount of cBiTE transcripts was higher than the amount of E1a viral transcripts (figure 
1g, white bars), and lower viral load (figure 1h) at the end of the experiment for ICOVIR15-
cBiTE groups (alone or using MenSCs as carriers) were observed. These results point a 
competitive scenario between viral genes and cBiTE in terms of transcription or translation. 
However, this reduced amount of cBiTE-armed virus was not correlated with a reduced 
antitumor activity, probably due to cBiTE effect.  
DISCUSSION 
In 2016, we reported an initial clinical experience in the use of CELYVIR (autologous 
mesenchymal stem cells infected with ICOVIR5, a previous version of ICOVIR15, in children 
with advanced neuroblastoma (NCT01844661)).10 Results from this clinical trial demonstrated 
good tolerance to the treatment and some clinical responses, including a complete remission. 
Over the last years, we have been trying to better understand the biology of MSCs after 
adenoviral infection and to develop an optimized CELYVIR version with enhanced antitumor 
properties and an easier production process. In previous work, we and others reported the 
advantages of using allogeneic MenSCs as cell carriers for OAdv tumor delivery.5, 9, 11 
Moreover, we pointed out the antitumor efficacy of MenSCs after OAdv infection in 
combination with human PBMCs. In this work we aimed at further improving the antitumor 
potential of our strategy by combining MenSCs with an EGFR BiTE-armed OAdv,6 Although 
the advantages of expressing BiTEs from genetically modified mesenchymal stem cells have 
been previously demonstrated,12 this is the first report on the benefit of the combination of 
MenSCs, BiTE immunotherapy and OAdv.  
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Our results prove proper cBiTE production from OAd-infected MenSCs, and an increased in 
vitro and in vivo cytotoxicity, confirming the existence of an improved tumor growth control by 
the cooperative action between OAd, cBiTE, and MenSCs. Of special interest for us is the in 
vivo antitumor efficacy comparison between the cBiTE-expressing versus the non-expressing 
OAdv in combination with MenSCs. Thus, the tumor growth difference between both groups is 
7, 20, 2.3 and 1.6- fold decrease at day 4, 7, 11 and 14 post-treatment, respectively, being always 
in favor of the MenSCs/ICOVIR15-cBiTE group.   
In summary, our results show that the combination of ICOVIR15-cBiTE and MenSCs could 
represent an attractive CELYVIR candidate for evaluation in clinical trials. 
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FIGURE LEGENDS 
Figure 1. (a) Schematic representation of the genome of the viruses used in the study. L/RITR, 
left/right inverted terminal repeats; SA, splicing acceptor; K, kozac sequence; pA, 
polyadenylation signal; S, signal peptide; F, flag tag. (b) Cytotoxicity assay of ICOVIR15 versus 
ICOVIR15-cBiTE. A549 cells were incubated with serial dilutions of each OAdv, from 200 to 0 
MOI. Cell viability was measured after 6 days and IC50 was calculated. The mean ± SD of 
triplicates is shown. (c) c-BiTE detection in supernatants from ICOVIR15 and ICOVIR15-cBiTE 
infected A549. A459 cells were incubated with concentrated supernatants from uninfected 
(Mock), ICOVIR15 (5 MOI) or ICOVIR15-cBiTE (5 MOI) infected cells and cBiTE binding 
was detected by flow cytometry. (d) cBiTE-mediated cytotoxicity in vitro. T-cells were co-
cultured with A431-GL (target cells) in the presence of the different supernatants (from 
ICOVIR15 and ICOVIR15-cBiTE infected MenSCs). Twenty-four hours after co-culture the 
percentage of cytotoxicity of target cells (GFP+L/D-) was assessed by flow cytometry. Bars, 
mean ± SD of triplicates. **, p<0.01 by Kruskal-Wallis with Dunn post-hoc test (e) Antitumor 
efficacy of OAdv-loaded MenSCs in vivo. NSG mice bearing subcutaneous A549 tumors 
received an intravenous injection of human allogeneic PBMCs. Next day, mice were 
intraperitoneally injected with PBS, ICOVIR15, ICOVIR15-cBiTE, MenSCs previously infected 
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with ICOVIR15 or MenSCs previously infected with ICOVIR15-cBiTE. Tumor volume was 
monitored every 3-4 days. The mean of tumor growth ± SEM is shown. *, P< 0.05, ***, P< 
0.001 MenSCs/ICOVIR15-cBiTE versus PBS group; #, P< 0.05 MenSCs/ICOVIR15-cBiTE 
versus ICOVIR15-cBiTE group; &, P< 0.05 MenSCs/ICOVIR15-cBiTE versus 
MenSCs/ICOVIR15 group by Kruskal-Wallis with Dunn post-hoc test. (f) Immunohistochemical 
staining of E1A of a representative tumor from each group is shown (scale bar 100μm). (g) 
cBiTE and E1A expression in tumors at the end of the experiment was determined by relative 
qRT-PCR using B-actin expression to normalize gene expression. Bars, mean ± SD of triplicates. 
* p<0.05, ** p<0.01 and *** p<0.001 by Kruskal-Wallis with Dunn post-hoc test (between 
different treatment groups) or by Mann Whitney U test (within each treatment group). (h) The 
presence of OAdv genomes in tumors at the end of the experiment was assessed by absolute 
qRT-PCR. Bars, mean ± SD of triplicates. ** p<0.01 by Kruskal-Wallis with Dunn post-hoc test.  
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